Neumora Therapeutics (NASDAQ: NMRA) net income
Neumora Therapeutics reported a net loss of $236.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $243.8m. Earnings per share were −$1.45.
Neumora Therapeutics's best year of the last 4 was fiscal 2022. It reported a loss in 4 of those 4 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$236.9m | — | — | −$1.45 |
| 2024 | −$243.8m | — | — | −$1.53 |
| 2023 | −$235.9m | — | — | −$3.63 |
| 2022 | −$130.9m | — | — | −$4.81 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Neumora Therapeutics net income compared with its sector
By net income for its latest fiscal year, Neumora Therapeutics ranks 428th of the 501 US health care companies with a page on Celsmar.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 426th | EyePoint | −$232.0m | −739.4% |
| 427th | Elanco Animal Health | −$232.0m | −4.9% |
| 428th | Neumora Therapeutics | −$236.9m | — |
| 429th | Surrozen | −$242.0m | −6,960.8% |
| 430th | LivaNova | −$242.5m | −17.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Neumora Therapeutics
- How much did Neumora Therapeutics earn in fiscal 2025?
- Neumora Therapeutics reported a net loss of $236.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $243.8m.
- What are the earnings per share of Neumora Therapeutics?
- They were −$1.45 in fiscal 2025, compared with −$1.53 in fiscal 2024.
- Where does Neumora Therapeutics rank in its sector by net income?
- It ranks 428th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Neumora Therapeutics come from?
- From the annual report (Form 10-K) that Neumora Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Neumora Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. More on Neumora Therapeutics: the Neumora Therapeutics page · annual accounts · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.